Emflaza

Active Ingredient(s): Deflazacort
FDA Approved: * February 9, 2017
Pharm Company: * MARATHON PHARMACEUTICALS LLC
Category: Anti-Inflammatory

Deflazacort (trade name Calcort among others) is a glucocorticoid used as an anti-inflammatory and immunomodulatory agent. It was patented in 1965 and approved for medical use in 1985.[1] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication for Duchenne Muscular Dystrophy.[2] Contents 1 Medical uses 2 Adverse effects 3 Pharmacology 3.1 Mechanism of action 3.2 Relative potency 4 History 5 References 6 External links ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Emflaza 6 mg Oral Tablet
NDC: 42998-501
Labeler:
Marathon Pharmaceuticals, LLC
Emflaza 18 mg Oral Tablet
NDC: 42998-502
Labeler:
Marathon Pharmaceuticals, LLC
Emflaza 30 mg Oral Tablet
NDC: 42998-503
Labeler:
Marathon Pharmaceuticals, LLC
Emflaza 36 mg Oral Tablet
NDC: 42998-504
Labeler:
Marathon Pharmaceuticals, LLC
Emflaza 22.75 mg/ml Oral Suspension
NDC: 42998-505
Labeler:
Marathon Pharmaceuticals, LLC
Emflaza 6 mg Oral Tablet
NDC: 52856-501
Labeler:
Ptc Therapeutics, Inc.
Emflaza 18 mg Oral Tablet
NDC: 52856-502
Labeler:
Ptc Therapeutics, Inc.
Emflaza 30 mg Oral Tablet
NDC: 52856-503
Labeler:
Ptc Therapeutics, Inc.
Emflaza 36 mg Oral Tablet
NDC: 52856-504
Labeler:
Ptc Therapeutics, Inc.
Emflaza 22.75 mg/ml Oral Suspension
NDC: 52856-505
Labeler:
Ptc Therapeutics, Inc.
More Results